ArticleArchives of endocrinology and metabolism2025
BRAF inhibitor or BRAF/MEK inhibitor treatment for patients with metastatic BRAF V600E mutated differentiated thyroid cancer.
Article in Archives of endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Uptake in thyroid Tripterygium glycosides, enhances radioiodine cancer by promoting the expression and function of NIS.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study is to demonstrate the real-life efficacy of BRAF and MEK inhibitors in patients with advanced thyroid cancer. SUBJECTS AND
methodsThis retrospective study evaluated the clinical efficacy of either a BRAF inhibitor (dabrafenib) alone or a BRAF inhibitor (dabrafenib) in combination with a MEK inhibitor (trametinib) in the treatment of 10 patients diagnosed with metastatic BRAF-mutant RAI refractory thyroid cancer. The primary endpoint was the investigator-assessed overall response rate (ORR).
resultsThe median patient age was 68 years, 60% were men, and all patients were diagnosed with progressive BRAF V600E-mutant RAI-refractory papillary thyroid carcinoma (PTC). In total, 70% of the patients had been previously treated with multikinase inhibitors. One (1%) patient received a BRAF inhibitor alone and 9 (90%) patients received a combination of BRAF and MEK inhibitors. After treatment, 2 (20%) patients achieved a complete response, 5 (50%) patients achieved a partial response, 1 (10%) patient experienced stable disease, and 1 (10%) patient experienced progressive disease. Seven (70%) patients had an objective response rate (ORR) (complete or partial response). Progression-free survival (PFS) was 70%, 40%, 30%, and 30% at 6, 12, 18, and 24 months, respectively. The 12-month overall survival (OS) rate was 90%.
conclusionDabrafenib in combination with trametinib was well tolerated and resulted in substantial clinical benefit, with notable PFS and sustained OS, even as a second-line treatment, in patients diagnosed with metastatic, progressive BRAF V600E-mutated, RAI-refractory thyroid cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.